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Abstract
Helicobacter pylori is a pathogen that establishes long life infections responsible for chronic gastric ulcer diseases and a
proved risk factor for gastric carcinoma. The therapeutic properties of carbon-monoxide releasing molecules (CORMs) led us
to investigate their effect on H. pylori. We show that H. pylori 26695 is susceptible to two widely used CORMs, namely
CORM-2 and CORM-3. Also, several H. pylori clinical isolates were killed by CORM-2, including those resistant to
metronidazole. Moreover, sub-lethal doses of CORM-2 combined with metronidazole, amoxicillin and clarithromycin was
found to potentiate the effect of the antibiotics. We further demonstrate that the mechanisms underpinning the
antimicrobial effect of CORMs involve the inhibition of H. pylori respiration and urease activity. In vivo studies done in key
cells of the innate immune system, such as macrophages, showed that CORM-2, either alone or when combined with
metronidazole, strongly reduces the ability of H. pylori to infect animal cells. Hence, CORMs have the potential to kill
antibiotic resistant strains of H. pylori.
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Introduction
Helicobacter pylori is a pathogen that colonizes the gastric mucosa
of humans and is ubiquitous in over half the world’s population.
Once acquired, H. pylori establishes lifelong infections that are the
major cause of gastric and duodenal ulcer diseases and malignant
gastric cancer [1]. H. pylori uses several factors that enable
colonization [2]. In particular, the activity of the nickel-dependent
urease is essential for the survival and pathogenesis of the
bacterium as this enzyme hydrolyses urea to ammonia, which
neutralizes the stomach acidity [3,4]. The more widely used
antibiotics for treatment of H. pylori are metronidazole, clarithro-
mycin, amoxicillin and tetracycline [5]. However, when given as
monotherapy none of these drugs are able to eradicate H. pylori.
Hence, infections with H. pylori are usually treated with a
combination of drugs, which consists of two or three antibiotics
together with an acid-suppressive drug (a proton pump inhibitor,
e.g. omeprazole) [5]. Yet, the efficacy of these multiple antibiotic
therapies is decreasing mainly due to the crescendo occurrence of
antibiotic-resistant H. pylori strains. In particular, metronidazole
resistant strains are a major cause of H. pylori treatment failure [6].
The endogenous production of carbon monoxide (CO), via the
mammalian heme oxygenase (HO), exerts benefits in the neural,
cardiovascular and renal systems [7]. Moreover, it has remarkable
impact on microbial sepsis as HO-1 deficient mice display
enhanced susceptibility to polymicrobial infections, and the
administration of exogenous CO rescues the HO-1-deficient mice
from sepsis-induced lethality [8,9]. The CO-releasing molecules
(CORMs) are metal carbonyls capable of transferring CO directly
to a target within a cell, which have been shown to represent a
more effective therapeutic way to deliver CO in mammals and
with potential for several medical applications [10–12]. The
release of CO from CORMs is triggered by light exposure, pH
variation or through ligand substitution. In particular, the
ruthenium-based carbonyl CORM-2 promotes carboxyl-myoglo-
bin formation upon dissolution in dimethyl sulfoxide, with a half
time of ,1 min. CORMs have been also reported to be stable
molecules at low pH, which represents an advantage for their
utilization in acidic environments [13,14]. In 2007, CORMs were
reported to have antimicrobial properties against Escherichia coli
and Staphylococcus aureus [15]. Since then, other bacteria such as
Pseudomonas aeruginosa and Mycobacterium tuberculosis showed to be
susceptible to CORMs [16,17]. Importantly, Ru2+ complexes
structurally similar to CORM-2 and CORM-3 but devoid of CO
do not kill bacteria, an observation that is consistent with the
inhibition of bacterial components by CO [15,18]. However, CO
alone is not as effective either, as the presence of the transition
metal carbonyl is required to elicit the antimicrobial action, which
relies on effects mediated by a network that involves CO liberation
and ROS formation [19]. Due to the emergence of H. pylori
resistance strains in this work we have tested the effectiveness of
CORMs against H. pylori under in vitro conditions and during
infection of mammalian cells.
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Materials and Methods
Reagents
Tricarbonylchloro(glycinato)ruthenium(II) (CORM-3, Alfama)
and tricarbonyldichlororuthenium(II) dimer (CORM-2, Sigma),
used as CO donors, were freshly prepared by dissolution in water
and dimethyl sulfoxide (DMSO), respectively. Dichlorotetrakis(di-
methylsulfoxide)ruthenium(II) dissolved in DMSO (Strem chem-
icals) was used as the CO-depleted form of Ru-based CORM-2
(herein named iCORM-2), and used in a concentration twice the
molar concentration of CORM-2. Metronidazole, amoxicillin,
and clarithromycin (Sigma) were dissolved in water.
Bacterial Strains, Growth Conditions and Viability Assays
Helicobacter pylori 26695 reference strain and six clinical strains,
isolated from human gastric biopsies and belonging to the
collection of Instituto Nacional de Sau´de Doutor Ricardo Jorge,
Portugal, were analysed. H. pylori strains were cultured, at 37uC,
under a microaerobic atmosphere (6% O2, 7% CO2, 3.5% H2 and
83.5% N2) generated by an Anoxomat system (MART Microbi-
ology). Growth was performed in 10% horse blood-agar (HBA,
Oxoid) plates and in brain heart infusion (BHI, Oxoid) liquid
medium, both supplemented with a cocktail of antibiotics/
fungicide (12.5 mg/L vancomycin, 0.3 mg/L polymyxin B,
6.3 mg/L trimethoprim and 5.0 mg/L amphotericin B). The
liquid medium was further supplemented with 10% (v/v)
decomplemented fetal calf serum (FCS, Gibco-Invitrogen) or with
0.2% b-cyclodextrin (bCD, Sigma).
To determine the susceptibility of H. pylori to CORMs, bacterial
suspensions (prepared as in Protocol S1) were inoculated at an
optical density at 600 nm (OD600) ,0.05 in BHI-bCD liquid
media and treated with CORM-3, CORM-2, iCORM-2 and/or
metronidazole. The number of viable cells was evaluated by
measuring the colony-forming unit per millilitre (CFU/mL)
formed on HBA plates. When indicated, H. pylori growth was
supplemented with 5 mM reduced glutathione (Sigma) or 5 mM
cysteine (Fluka).
The minimal inhibitory concentration (MIC) and the minimal
bactericidal concentration (MBC) were determined [20] for
CORM-3, CORM-2, metronidazole, amoxicillin and clarithro-
mycin (as described in Protocol S2).
Oxygen Consumption Assays and Spectrophotometric
Analysis of Cytochromes
Oxygen consumption assays were done in bacterial suspensions
(prepared as detailed in Protocol S3) treated for 5 min with
CORM-2 (25 mg/L), iCORM-2 (50 mg/L) or left untreated and
stimulated by addition of sodium pyruvate (5 mM), and monitored
in a Rank Broths oxygen electrode (Hansatech).
H. pylori cells grown for 24 h on HBA plates were resuspended
in 20 mM Tris-HCl pH 7.5 and incubated with lysozyme for
30 min at 37uC. Cells were then centrifuged for 30 min at
12000 g to collect cell debris. The supernatants containing
membranes and cytoplasm were reduced by addition of a
saturated buffered solution of sodium dithionite and treated with
200 mg/L CORM-2, for 2 min. Spectra were recorded in a
Shimadzu UV-1700 spectrophotometer and the reduced-plus-
CORM-2 minus reduced difference spectra was calculated.
Urease Activity Assays
Urease activity was determined in cellular suspensions of H.
pylori grown, for 15 h, in the absence and in the presence of
200 mg/L CORM-2 or 400 mg/L iCORM-2. Also, cellular
suspensions of H. pylori grown for 24 h on HBA plates in the
absence of any carbon monoxide source were collected and
exposed, for 15 min, to several concentrations of CORM-2.
Urease activity was determined spectrophotometrically at 560 nm
[21] in 50 mL cellular suspensions (prepared as described above
and detailed in Protocol S3) that were incubated, for 30 min, with
500 mL 0.7 mM KH2PO4 Na2HPO4 (pH 6.9) buffer, 300 mM
urea (Sigma) and 0.1 mM phenol red (Sigma).
Helicobacter pylori Viability in Macrophages
Murine macrophage cell line RAW264.7 (ATCC Tib71) was
seeded with 56105 cells per well, in 24-well plates (Sarstedt)
containing Dulbecco’s modified Eagle’s medium (see Protocol S4)
and grown for 3 h at 37uC in humidified 5% CO2 atmosphere. At
this point, macrophages were activated with 0.3 mg/mL gamma
interferon (IFN-c, Sigma) for 12 h. Bacterial suspensions were
used to infect macrophages cultured in infection medium, at a
multiplicity of infection (MOI) of,100. After incubation for 3 and
6 h, at 37uC and 5% CO2, each well was scraping to evaluate the
viable bacterial cells (see details in Protocol S4).
Statistical Analyses
Statistical analyses were performed with GraphPad Prism 5
(GraphPad Software) using, as indicated, either One-way or Two-
way ANOVA followed by a Bonferroni multiple comparison test.
Analysis of the MIC and MBC data was done with the Mann
Whitney t test considering the significance threshold at P,0.05
(95% confidence level). Data are presented as mean 6 standard
error (SE), with exception for MICs and MBCs represent medians.
Results
Helicobacter pylori Viability Is Inhibited by CORMs
To examine how CORMs affect the growth of H. pylori 26695,
CORM-2 and CORM-3 were added to cultures growing in BHI-
bCD under microaerobic conditions. Both CORMs inhibited
viability during 20 h, in a concentration-dependent manner
(Fig. 1). The effect mediated by CORM-2 was stronger than that
exerted by CORM-3. Exposure of H. pylori to 200 mg/L CORM-
2, for 15 h, induced a 4-log loss of cell viability (Fig. 1A), while
treatment with 300 mg/L CORM-3 lowered the viability by 2-log
(Fig. 1B). Interestingly, the decrease of the H. pylori counts caused
by 300 mg/L CORM-2 was comparable to that induced by
1.5 mg/L metronidazole (Fig. 1A and S1). Values of 200 and
250 mg/L (CORM-2) and 420 and 510 mg/L (CORM-3) were
obtained for the MIC and MBC, respectively. Furthermore, the
ratio MBC/MIC was lower than 4 revealing the bactericidal
character of the two drugs [22].
Some antibiotics were reported to stimulate the formation of
coccoid forms [23], therefore, we tested whether CORMs promote
similar modifications. However, even after 20 h exposure to
200 mg/L CORM-2, the shape of the treated cells remained
unaltered and the presence of coccoid forms was not observed
(data not shown).
As CORMs are ruthenium-containing compounds we have
analysed whether the transition metal contributed to the
antimicrobial properties by growing H. pylori in the presence of
the CO-depleted compound but that still contains ruthenium,
namely iCORM-2. However, up to 400 mg/L iCORM-2 elicited
no growth impairment (Fig. S2), revealing that the metal does not
interfere and CO is required for the bactericidal effect.
Since H. pylori is more effectively killed by CORM-2, the
following experiments were performed with this compound.
CORMs Kill H. pylori
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CORM-2 Impairs H. pylori Respiration
Since CORM-2 showed to be an inhibitor of H. pylori growth,
we sought whether CORM-2 inhibited cellular respiration. While
H. pylori cells left untreated and stimulated with pyruvate had a
considerable oxygen reductase specific activity (,1.2 nmol O2/
min/CFU), incubation with CORM-2 for 5 min caused a
decrease of more than 50% in oxygen (Fig. 2A). Furthermore,
the difference spectrum of H. pylori cells treated with CORM-2
(reduced-plus-CORM-2 minus reduced, Fig. 2B) shows a Soret
band at 418 nm with a trough at 433 nm and bands at 535 and
570 nm, with a trough at 585 nm. These features are character-
istic of the in vivo formation of carbonmonoxy adducts binding
cytochrome b and c, and have been proposed to arise from the
ligation of CO to cbb3-type cytochrome oxidase, so far the sole
terminal oxidase cytochrome of H. pylori [24,25].
We observed that addition of glutathione and cysteine prevents
bacterial killing by CORM-2 (Fig. 2C). However, no formation of
reactive oxygen species ROS could be detected and supplemen-
tation with ascorbic acid did not inhibit the CORM-2 antimicro-
bial action (data not shown). Although similar results were
previously reported for CORM-3-treated Pseudomonas aeruginosa,
the rational behind abolishment of the CORM bactericidal effect
by thiol donors remains essentially unclear [16].
Figure 1. CORMs affect H. pylori viability. Cell viability of H. pylori
26695 left untreated (filled circle) and treated with 100, 150 and
200 mg/L CORM-2 (open square, triangle and diamond, respectively)
(A), and exposed to 120, 240 and 300 mg/L CORM-3 (open diamond,
inverted triangle and circle, respectively) (B). The number of viable cells
were determined for four biological samples and are expressed as
means6 SE. *p,0.05, **p,0.01 and ***p,0.001 (Two-way ANOVA and
Bonferroni test).
doi:10.1371/journal.pone.0083157.g001
Figure 2. CORM-2 inhibits H. pylori respiration. (A) Cellular
suspensions of H. pylori were left untreated (black) and treated for
5 min with 50 mg/L iCORM-2 (grey) and 25 mg/L CORM-2 (white).
Oxygen consumption was measured, after the addition of pyruvate
(5 mM) in a Clark-type O2 electrode for two biological samples of H.
pylori assayed in triplicate. Values are expressed as means 6 SE.
***p,0.001, ns - non significant (One-way ANOVA and Bonferroni test).
(B) Spectral characterization of H. pylori cells treated with CORM-2.
CORM-2 (200 mg/L) was added to reduce cells of H. pylori and the
spectra recorded 5 min after addition of compound. Numbers indicate
wavelength features (nm) in the difference reduced-plus-CORM-2 minus
reduced spectrum. Two independent biological samples were analyzed.
(C) Viability of H. pylori grown in BHI-bCD medium (black) and exposed
to 200 mg/L CORM-2 alone (white), and in the presence of 5 mM
glutathione (dark grey) or 5 mM cysteine (light grey). Values represent
average of three biological samples with the respective SE.
doi:10.1371/journal.pone.0083157.g002
CORMs Kill H. pylori
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CORM-2 Inhibits H. pylori Urease Activity
H. pylori expresses significant amounts of a nickel-containing
urease, which is a key enzyme for its virulence [3]. Since CO is
able to bind transition metals, we analysed the effect of CORM-2
in the urease activity in: i) cells grown in the presence of CORM-2
and ii) cells growth in the absence of the CO donor, collected and
then exposed to several concentrations of CORM-2. The results
showed that H. pylori grown in the presence of 200 mg/L CORM-
2 exhibited a urease activity decrease of ,65% (Fig. 3A). Also, the
incubation of H. pylori cells with increasing concentrations of
CORM-2, for 15 min, cause impairment of the urease activity.
Using CORM-2 concentrations up to 200 mg/L, a value of half-
maximal inhibitory concentration IC50 of 661 mg/L was
determined (Fig. 3B).
CORM-2 Is Able to Kill Metronidazole-Resistance H. pylori
Strains
We investigated the toxicity of CORMs towards six H. pylori
clinical strains with different degree of metronidazole resistance
(Table 1). All these strains were isolated from patients suffering
from non-ulcer dyspepsia, and present different antibiotic resis-
tance profiles to metronidazole and clarithromycin. Strains 4574,
5587, 5611 and 5846 are resistant to both antibiotics, the 5599
strain is susceptible to metronidazole and resistant to clarithro-
mycin and the 4597 strain is resistant to metronidazole and
susceptible to clarithromycin. Additionally, they are all susceptible
to amoxicillin.
The clinical isolates showed different susceptibility to CORM-2,
with MICCORM-2 values ranging from 100 and 200 mg/L
(Table 1). Moreover, CORM-2 acted as a bactericidal since the
MBC/MIC ratios determined were lower than four (Table S1).
While the highest MICs of CORM-2 (MICCORM-2 = 200 mg/L)
were observed for the metronidazole-susceptible strains, (Table
S1), the growth of metronidazole-resistant clinical isolates
(MICmetronidazole .8 mg/L) was inhibited by lower concentrations
of CORM-2 (MICCORM-2#150 mg/L). The only exception
occurred for the metronidazole-resistant strain 4597, which
exhibited the same MIC for CORM-2 than the metronidazole-
susceptible strains (Table S1).
Combination of CORM-2 and Antibiotics Attenuates In
H. pylori Viability
Since H. pylori infections are usually eradicated by means of
triple or even quadruple therapies, we analysed the effect of
CORM-2 as an adjuvant of the currently used antibiotics. For this
purpose, H. pylori was treated with metronidazole, amoxicillin or
clarithromycin combined with a sub-lethal dose of CORM-2.
Non-significant loss of viability was observed upon exposure of H.
pylori to metronidazole (1.5 mg/L) (#2-log) or to CORM-2
(100 mg/L). However, simultaneous exposure to the two drugs
resulted in an accentuated drop in recovered viable bacteria (,4-
log) (Fig. 4). The combination of CORM-2 and metronidazole
translated into a reduction of 50% of the MIC for metronidazole
(Fig. 5 and Table S2). Likewise, the combination of CORM-2 with
amoxicillin and clarithromycin led to a significant decrease of both
MIC and MBC that, similarly to metronidazole, was dependent
on the CORM-2 concentration (Fig. 5 and Table S2).
The effect of combining metronidazole with CORM-2 was also
tested for H. pylori clinical isolates. At least, a two-fold decrease of
the MIC for metronidazole was observed in all cases, with the
highest metronidazole resistant strains exhibiting the more
significant drop of the MIC and MBC values (Fig. 6). For
example, the clinical isolate 5611 (MICmetronidazole = 64 mg/L)
become susceptible (MIC for metronidazole = 8 mg/L) when the
metronidazole was administrated together with 100 mg/L
CORM-2 (Tables S3 and S4).
Figure 3. CORM-2 inhibits urease activity of H. pylori. (A) Urease
activity was measured in H. pylori cells left untreated (black), treated for
15 h with 400 mg/L iCORM-2 (grey) and 200 mg/L CORM-2 (white). The
results represent the average of three biological samples performed in
duplicate, and error bars represent SE. ***p,0.001, ns - non significant
(One-way ANOVA and Bonferroni test). (B) Urease activity of H. pylori
cell suspensions treated, for 15 min, with CORM-2 (0, 2.5, 5, 12.5, 25, 50,
100 and 200 mg/L). The results are the average of five biological
samples and error bars represent SE.
doi:10.1371/journal.pone.0083157.g003
Table 1. MICs of CORM-2 and metronidazole to the H. pylori
reference strain 26695 and the indicated clinical isolates.
MIC (mg/L)
Strain CORM-2 Metronidazole*
26695 200 8
5599 200 2
5611 150 64
5846 100 16
4597 200 32
4574 150 32
5587 100 32
*Resistant (MIC.8 mg/L).
doi:10.1371/journal.pone.0083157.t001
CORMs Kill H. pylori
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Vitro
CORM Treated H. pylori Compromises Bacterial Survival in
Macrophages
Since H. pylori is known to activate the innate immune system
we have evaluated the effect of CORM-2 upon H. pylori infection
of murine macrophages. H. pylori cells unexposed or exposed to
iCORM-2 and CORM-2 were incubated with activated
RAW264.7 macrophages and their viability evaluated. For similar
viable bacterial loads, the iCORM-2-treated H. pylori was as
resistant to macrophages as untreated bacterial cells. On the
contrary, the survival of the CORM-2-treated H. pylori was
approximately 98% lower in comparison to cells exposed to
iCORM-2 (Fig. 7A).
Combined CORM-2-Metronidazole Further Reduces
Survival of H. pylori in Macrophages
Given that the combination of CORM-2 with metronidazole
reduced the in vitro viability of H. pylori, we next determined the
survival of the double-treated H. pylori when in contact with
activated macrophages. While no significant alteration was seen
when infecting macrophages with H. pylori treated with CORM-2
(100 mg/L) or iCORM-2 (200 mg/L) alone, a small decrease in
the survival (,30%) was observed for cells exposed to metroni-
dazole or metronidazole plus the iCORM-2 (Fig. 7B). However,
treatment of H. pylori with CORM-2 (100 mg/L) combined with
metronidazole (1.5 mg/L) exhibited a ,98% decrease in bacterial
count upon macrophage infection. This allows concluding that the
co-administration of metronidazole-CORM-2 renders H. pylori
more susceptible to macrophage killing.
Discussion
The current work reveals that CORMs are effective against H.
pylori with CORM-2 being more effective than CORM-3. This
difference is likely to originate from the different reactivity and
physical-chemical properties (e.g. hydrophobicity, polarity, H-
bonding ability, etc.) imparted to both complexes by their outer
coordination spheres [12]. In particular, CORM-2 is more
hydrophobic than CORM-3, which may favour the interaction
of CORM-2 with the medium and the bacterial cells. We also
observed that Ru2+ complexes are not toxic as iCORM-2 does not
decrease H. pylori viability, indicating that the bactericidal action of
CORM-2 relies on inhibition of the bacterial components by CO.
In agreement, inhibition of H. pylori growth by CORM-2 is
accompanied by a decrease in the rate of cellular oxygen
consumption due to the binding of CORM-2-derived CO to the
H. pylori terminal oxidase. Similar findings were reported for other
bacteria [16,25,26]. Moreover, CORM-2 impairs the urease
activity, which is a nonheme target, most probably due to the
ligation of CO to nickel for which CO has high affinity [27]. Due
to the crucial role of urease in the persistence of H. pylori in the
gastric niche [3], a urease inhibitor such as CORM-2 gains
relevance as a novel way to control this infection. Moreover, and
contrary to other potent urease inhibitors such as acetohydroxa-
mic acid and fluorofamide [28,29], these CORMs preserve their
Figure 4. Effect of combined metronidazole and CORM-2
treatment on H. pylori viability. Cell viability of H. pylori 26695 left
untreated (black) and exposed to iCORM-2 (dark grey), 100 mg/L
CORM-2 (white), 1.5 mg/L metronidazole (light grey), 1.5 mg/L metro-
nidazole plus 200 mg/L iCORM-2 (light grey, diagonal strips) and
1.5 mg/L metronidazole plus 100 mg/L CORM-2 (light grey, horizontal
strips). The number of viable cells were determined for four
independent cultures and are expressed as means 6 SE. ***p,0.001
(Two-way ANOVA and Bonferroni test).
doi:10.1371/journal.pone.0083157.g004
Figure 5. Effect of CORM-2 on MIC/MBC values of metronidazole, amoxicillin and clarithromycin for H. pylori. MICs (A) and MBCs (B) of
metronidazole (MTZ), amoxicillin (AMX) and clarithromycin (CH) against H. pylori 26995 determined in the absence (black) and in the presence of
100 mg/L (dark grey) and 150 mg/L CORM-2 (light grey). Results represent the median of five biological samples and are significantly different in all
cases (p,0.05 in Mann Whitney t test).
doi:10.1371/journal.pone.0083157.g005
CORMs Kill H. pylori
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stability at low pH values [14], representing a clear advantage for
H. pylori treatment as they must be active in the acidic environment
of the stomach.
Although our data show that CORM-derived CO affected two
metal containing enzymes, namely the heme containing terminal
oxidases and Ni-containing urease, it is likely that these will not be
the sole targets, since CO has a high affinity for metals and may
bind other metal containing enzymes and proteins, including
regulators like Fur or NikR.
Another interesting feature of CORM-2 is the apparent lack of
alterations of the morphologic traits in H. pylori cells treated with
this compound, revealing that CORM-2 does not induce the
formation of coccoid forms, which in several cases are associated
with development of H. pylori antibiotic resistance [30].
For H. pylori, approximately 200 mg/L (,400 mM) CORM-2
was required to decrease viability by more than 99.99%, while for
E. coli, S. aureus and P. aeruginosa the inhibitory concentration
ranged from 100–500 mM [15,16]. Although the concentrations
required to kill a pathogen are certainly related with the type of
microorganism, the growth medium and the experimental
conditions also contribute to the amounts required in each case.
The hitherto available data indicates that bacteria cultivated in
minimal media are killed by concentrations of CORMs that are
lower than those required to eliminate bacteria cultured in rich
media [15]. The lack of effect observed on H. pylori when using
,100 mM CORM-2 or CORM-3 is consistent with the failure
also reported for C. jejuni grown in rich medium and exposed to
100 mM CORM-3 [25]. Like Campylobacter jejuni, H. pylori is a slow
growth pathogen that requires rich medium to proliferate in vitro.
Therefore, only concentrations above 300 mM were effective for
H. pylori.
In spite of the high concentrations of CORM-2 used here to kill
H. pylori, it is worth noting that they were determined under in vitro
conditions. These are likely very different from those expected at
the in vivo environment, as several factors will influence the
amounts required to eradicate H. pylori, which include the acidity
and oxygen conditions of the milieu at the site of infection.
Nevertheless, CORM-2 and CORM-3 used in concentrations up
to 500 mM are not toxic to mammalian cells [13,16,31].
Moreover, CORMs seem to be biologically effective as treatment
of mice with an intraperitoneal injection significantly decreased
the P. aeruginosa counts in spleen and the mortality of mice without
any sign of toxicity [16].
Treatment failures are common in patients infected with H.
pylori strains resistant to metronidazole, which is one of the
antibiotics currently used in therapy of H. pylori [5]. We proved
that metronidazole-resistant clinical strains are eliminated by
CORM-2. Moreover, combination of CORM-2 with metronida-
zole is more effective at killing H. pylori than either drug alone, and
enhances the killing promoted by macrophages. Furthermore, the
present results suggest that CORM-2 has the potential to eradicate
amoxicillin and clarithromycin resistant H. pylori strains, as the
combination of both drugs also decreased the MIC for amoxicillin
and clarithromycin against H. pylori 26695 reference strain.
Although the resistance to metronidazole can be overcome by
increasing the dose and duration of the therapy, it may lead to
intolerable side effects [5]. In this way, the use of CORM-2 as co-
adjuvant may represent an alternative treatment.
Recently, it was reported that although the ruthenium-based
carbonyl ALF492 does not have an antiparasitic effect, it enhances
the action of the antimalarial drug artesunate [32]. Also, CORM-
2 combined with tobramycin, a drug used to treat P. aeruginosa lung
infections, seems to prevent biofilm formation [33]. However,
some of the P. aeruginosa clinical isolates tested were not susceptible
to CORM-2 suggesting that it may not work for all P. aeruginosa
infections. On the contrary, all H. pylori clinical strains herein
examined were susceptible to CORM-2, including those resistant
to metronidazole and to clarithromycin.
Treatment of H. pylori infections with CORMs may have further
impact that is not strictly related with the elimination of the
bacterium. One of the hallmarks of H. pylori infection is the
induction of a state of chronic inflammation in the gastric mucosa,
which H. pylori exploits to promote epithelial erosion and to
acquire essential nutrients. CO is produced by the human HO-1
enzyme as a natural mechanism of controlling and reducing the
inflammatory response. Application of exogenous CO also
Figure 6. CORM-2 lowers MIC and MBC of metronidazole for H. pylori clinical isolates. (A) MIC of metronidazole determined for each H
pylori clinical isolate in the absence (grey) and in the presence of CORM-2 (black). Strains 5846 and 5587 were treated 50 mg/CORM-2, strains 5611
and 4574 exposed to 100 mg/L CORM-2, and strains 5599 and 4597 submitted to 150 mg/L CORM-2. (B) MBC of metronidazole for each H pylori
clinical isolates, in the absence (grey) and in the presence of CORM-2 (black). Strains 5846 and 5587 were treated 200 mg/CORM-2, and strains 5611,
4574, 5599 and 4597 exposed to 150 mg/L CORM-2. For each strain, metronidazole was combined with a CORM-2 concentration below the MIC/MBC
of the CORM-2 alone. In all cases, values representing the median of five biological samples were significantly different (p,0.05 in Mann Whitney t
test).
doi:10.1371/journal.pone.0083157.g006
CORMs Kill H. pylori
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protects against inflammation and CORMs have been used as
therapies to decrease undesired inflammatory responses [10,34].
Hence, the use of CORMs against H. pylori may constitute a
source of CO release in the gastric lumen potentially contributing
to the decrease of mucosal inflammation, which is a major cause
for the development of malignant lesions. Indeed, it has been
shown that CO delivered by ALF186 ([Mo(CO)3(histidinato)]Na)
is biologically active in the stomach providing protection against
the inflammation and gastric ulcer caused by indomethacin [35].
Most likely relevant to the same issue is the fact that ruthenium
CORMs like CORM-3 and ALF492 induce HO-1, which results
in a reinforcement of their anti-inflammatory action [32]. Besides
contributing to cytoprotection [9], CORMs may also promote
reinforcement of the innate immune system as we show that
CORM-2-treated H. pylori has a very low survival in macrophages.
In conclusion, this work provides the first evidence that
CORMs act as antimicrobials either alone or in combination
with antibiotics currently used to H. pylori. This is important data
since chronic colonization with H. pylori antibiotic-resistant strains
is difficult to eradicate and combined therapies are among the
more effective means to combat resistant strains.
Supporting Information
Figure S1 Effect of metronidazole on H. pylori viability.
H. pylori 26695, grown as described in Material and Methods, was
treated with 1.5 and 2 mg/L metronidazole (black and white
squares, respectively) or left untreated (black circles). Cell viability
was analyzed at the indicated times by determining CFU/mL.
Values are average of two biological samples with the respective
SE.
(TIF)
Figure S2 iCORM-2 has no effect on H. pylori viability.
H. pylori 26695 left untreated (black bar) and after exposure to 200,
300 and 400 mg/L iCORM-2 (dark grey, white and light grey
bars, respectively). Cell viability was determined as described in
Material and Methods. Values represent the average of three
biological samples with SE.
(TIF)
Table S1 MIC and MBC of CORM-2 (mg/L) and
metronidazole (mg/L) for the reference strain 26695
and the indicated clinical isolates of H. pylori.
(DOCX)
Table S2 MIC and MBC (mg/L) of metronidazole
(MTZ), clarithromycin (CH) and amoxicillin (AMX) for
H. pylori 26695 determined in the presence of sub-lethal
doses of CORM-2.
(DOCX)
Table S3 MIC of metronidazole (mg/L) combined with
sub-lethal doses of CORM-2 (mg/L) for clinical isolates
of H. pylori.
(DOCX)
Table S4 MBC of metronidazole (mg/L) combined with
sub-lethal doses of CORM-2 (mg/L) for clinical isolates
of H. pylori.
(DOCX)
Protocol S1 Growth conditions for viability assays. To
determine the susceptibility of H. pylori to CORMs, cells cultured
on HBA plates for 24 h were used to inoculate 10 mL of BHI-FCS
liquid media contained in 25 cm3 cell culture flasks (Nunc) at an
optical density at 600 nm (OD600) ,0.05. After 16 h, these
cultures were used as starter cultures to inoculate H. pylori in
10 mL BHI-bCD at an OD600 ,0.05. At this point, CORM-3,
CORM-2, iCORM-2 and/or metronidazole were added and
growth was monitored by recording the OD600 for the next 20 h.
At selected times, the number of viable cells was evaluated by
measuring the colony-forming unit per millilitre (CFU/mL)
formed upon plating serial dilutions on HBA plates, which were
incubated three days.
(DOC)
Protocol S2 Determination of MIC and MBC. Starting
cultures of H. pylori 26695 and clinical isolates, prepared as
described above, were used to inoculate fresh BHI-bCD medium
to an OD600 of ,0.05, and aliquots of 1.2 mL were distributed in
24-well plates (Sarstedt). For each antibiotic the following range of
concentrations were used with increasing doubling concentrations:
Figure 7. H. pylori is more susceptible to macrophage killing
when treated with CORM-2. Macrophages RAW264.7, pre-activated
with IFN-c (0.3 mg/mL) for 12 h, were infected with H. pylori (MOI
,100). In (A) H. pylori untreated (black), treated with 400 mg/L iCORM-
2 (grey) or with 200 mg/L CORM-2 (white) was used. For (B) H. pylori not
exposed (black), submitted to 200 mg/L iCORM-2 (dark grey), 100 mg/L
CORM-2 (white), 1.5 mg/L MTZ (light grey), MTZ plus iCORM-2 (grey,
diagonal strips), and MTZ combined with 100 mg/L CORM-2 (grey,
horizontal strips) was assayed. In all cases, bacterial survival was
determined after 3 and 6 h of infection, and results are the average of
five biological samples analysed in triplicate. Error bars represent SE.
*p,0.05, **p,0.01, ns - non significant (Two-way ANOVA and
Bonferroni test).
doi:10.1371/journal.pone.0083157.g007
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metronidazole 0.5–256 mg/L, amoxicillin 0.001–0.250 mg/L and
clarithromycin 0.001–0.250 mg/L. The range of CORM-3 and
CORM-2 concentrations varied from 50 to 600 mg/L, with
50 mg/L intervals. After microaerobic incubation for 72 h, at
37uC and 90 rpm, MICs were determined by reading the OD600.
For the MBCs determination, 10 mL of each culture was then
plated on HBA medium and incubated for another 72 h and the
lowest concentration that prevented formation of colonies was
considered the MBC.
(DOC)
Protocol S3 Preparation of H. pylori cellular suspension
for oxygen consumption assays and urease activity. To
determine the rate of oxygen consumption, starting cultures of H.
pylori 26695, prepared as described above, were used to inoculate
fresh BHI-bCD medium to an OD600 of ,0.05. Then, after 15 h,
cultures were harvested by centrifugation (5 min, 120006g, 4uC),
washed and resuspended in 10 mM potassium phosphate buffer
(pH 7.0). This cellular suspension was further incubated for 5 min
with CORM-2 (25 mg/L), iCORM-2 (50 mg/L) or left untreated,
and used for oxygen consumption assays. To measure urease
activity in H. pylori, starting cultures, prepared as described above,
were used to inoculate fresh BHI-bCD medium to an OD600 of
,0.05. H. pylori was grown for 15 h, in BHI-bCD in the absence
and in the presence of 200 mg/L CORM-2 or 400 mg/L
iCORM-2. Before analysis, cultures were diluted, to achieve a
final concentration of 16108 CFU/mL (OD600 ,0.1). The effect
of CORM-2 was also evaluated in cellular suspensions in vitro,
treated for 15 min with increasing concentrations of CORM-2. In
this case, a H. pylori suspension was prepared, using cells grown for
24 h on HBA plates, in PBS at 26108 CFU/mL (OD600 ,0.2),
and treated with CORM-2 (0, 2.5, 5, 12.5, 25, 50, 100 and
200 mg/L) for 15 min.
(DOCX)
Protocol S4 Macrophages Experiments. The Dulbecco’s
modified Eagle’s medium used to cultivate macrophages contains
4.5 g/L glucose and 110 mg/mL sodium pyruvate (DMEM
glutamaxTM, Gibco-Invitrogen) and is supplemented with 10%
FCS, 70 U/mL penicillin and 70 mg/mL streptomycin (Gibco-
Invitrogen). Cultures of H. pylori 26695, grown as described above
for the viability assays, in the presence of CORM-2, iCORM-2
and/or metronidazole for 15 h, were washed three times with PBS
(pH 7.4) and resuspended in infection medium containing DMEM
glutamaxTM supplemented with 10% FCS, without addition of
antibiotics, at an initial bacterial content of ,56108 CFU/mL.
Bacterial suspensions (100 mL) were used to infect macrophages
cultured in infection medium, at a multiplicity of infection (MOI)
of ,100. After incubation for 3 and 6 h, at 37uC and 5% CO2,
each well was scraping to release adherent cells and resuspended in
BHI medium; viable bacterial cells were then evaluated by plating
serial dilutions onto HBA plates, which were incubated for 3 days.
The values were normalized to the initial value of CFU/mL, i.e
the CFU of the culture immediately before been used to infect
macrophages, and the survival percentage determined by dividing
the number of colonies of treated cultures by those of untreated
cultures.
(DOCX)
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